Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge

Neuropharmacology

Volumn 58, Issue 3, 2010, Pages 632-639

  Fell, Matthew J ^a   Katner, Jason S ^a   Johnson, Bryan G ^a   Khilevich, Albert ^a   Schkeryantz, Jeffrey M ^a   Perry, Kenneth W ^a   Svensson, Kjell A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

CBiPES; Histamine; In vivo microdialysis; Ketamine; LY379268; mGlu2 3 receptors

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; KETAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; HISTAMINE RELEASE; LIMBIC SYSTEM; MALE; MICRODIALYSIS; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCHEMISTRY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HISTAMINE; INDOLES; KETAMINE; LIMBIC SYSTEM; MALE; MICRODIALYSIS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 73449116350     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.11.014     Document Type: Article

References (38)

1. Aggleton J.P., Vann S.D., and Saunders R.C. Projections from the hippocampal region to the mammillary bodies in macaque monkeys. Eur. J. Neurosci. 22 (2005) 2519-2530
2. Brown R.E., Stevens D.R., and Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 63 (2001) 637-672
3. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 68 (2004) 1507-1514
4. Danysz W., Essmann U., Bresink I., and Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48 (1994) 111-118
5. Danysz W., Wroblewski J.T., and Costa E. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27 (1988) 653-656
6. Ericson H., Blomqvist A., and Kohler C. Origin of neuronal inputs to the region of the tuberomammillary nucleus of the rat brain. J. Comp. Neurol. 311 (1991) 45-64
7. Faucard R., Armand V., Heron A., Cochois V., Schwartz J.C., and Arrang J.M. N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J. Neurochem. 98 (2006) 1487-1496
8. Fell M.J., Johnson B.G., Svensson K.A., and Schoepp D.D. Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J. Pharmacol. Exp. Ther. 326 (2008) 209-231
9. Itoh Y., Oishi R., Nishibori M., and Saeki K. Phencyclidine and the dynamics of mouse brain histamine. J. Pharmacol. Exp. Ther. 235 (1985) 788-792
10. Iwabuchi K., Ito C., Tashiro M., Kato M., Kano M., Itoh M., Iwata R., Matsuoka H., Sato M., and Yanai K. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur. Neuropsychopharmacol. 15 (2005) 185-191
11. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
12. Kishi T., Tsumori T., Ono K., Yokota S., Ishino H., and Yasui Y. Topographical organization of projections from the subiculum to the hypothalamus in the rat. J. Comp. Neurol. 419 (2000) 205-222
13. Kubota T., Hirota K., Yoshida H., Takahashi S., Ohkawa H., Anzawa N., Kushikata T., and Matsuki A. Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats. Br. J. Anaesth. 83 (1999) 945-947
14. Lindefors N., Barati S., and O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 759 (1997) 205-212
15. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 (2003) 697-706
16. Lorrain D.S., Schaffhauser H., Campbell U.C., Baccei C.S., Correa L.D., Rowe B., Rodriguez D.E., Anderson J.J., Varney M.A., Pinkerton A.B., Vernier J.M., and Bristow L.J. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28 (2003) 1622-1632
17. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to sopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (1997) 2921-2927
18. Moghaddam B., and Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281 (1998) 1349-1352
19. Nakai T., Kitamura N., Hashimoto T., Kajimoto Y., Nishino N., Mita T., and Tanaka C. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol. Psychiatry 30 (1991) 349-356
20. Okakura-Mochizuki K., Mochizuki T., Yamamoto Y., Horii A., and Yamatodani A. Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat. J. Neurochem. 67 (1996) 171-176
21. Okamura N., Yanai K., Higuchi M., Sakai J., Iwata R., Ido T., Sasaki H., Watanabe T., and Itoh M. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br. J. Pharmacol. 129 (2000) 115-123
22. Parada-Turska J., and Turski W.A. Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks. Neuropharmacology 29 (1990) 1111-1116
23. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13 (2007) 1102-1107
24. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press.
25. Perry K.W., Falcone J.F., Fell M.J., Ryder J.W., Yu H., Love P.L., Katner J., Gordon K.D., Wade M.R., Man T., Nomikos G.G., Phebus L.A., Cauvin A.J., Johnson K.W., Jones C.K., Hoffmann B.J., Sandusky G.E., Walter M.W., Porter W.J., Yang L., Merchant K.M., Shannon H.E., and Svensson K.A. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55 (2008) 743-754
26. Prell G.D., Green J.P., Kaufmann C.A., Khandelwal J.K., Morrishow A.M., Kirch D.G., Linnoila M., and Wyatt R.J. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr. Res. 14 (1995) 93-104
27. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299 (2001) 12-20
28. Schoepp D.D., and Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 215-225
29. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., and Ruat M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 71 (1991) 1-51
30. Sherin J.E., Elmquist J.K., Torrealba F., and Saper C.B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 18 (1998) 4705-4721
31. Spooren W.P.J.M., Gasparini F., van der Putten H., Koller M., Nakanishi S., and Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur. J. Pharmacol. 397 (2000) R1
32. Stevens D.R., Kuramasu A., and Haas H.L. GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro. Eur. J. Neurosci. 11 (1999) 1148-1154
33. Swanson C.J., and Schoepp D.D. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann. N. Y. Acad. Sci. 1003 (2003) 309-317
34. Westerink B.H., Cremers T.I., De Vries J.B., Liefers H., Tran N., and De Boer P. Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat. Synapse 43 (2002) 238-243
35. Woolley M.L., Pemberton D.J., Bate S., Corti C., and Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196 (2008) 431-440
36. Wouterlood F.G., Steinbusch H.W., Luiten P.G., and Bol J.G. Projection from the prefrontal cortex to histaminergic cell groups in the posterior hypothalamic region of the rat. Anterograde tracing with Phaseolus vulgaris leucoagglutinin combined with immunocytochemistry of histidine decarboxylase. Brain Res. 406 (1987) 330-336
37. Yang Q.Z., and Hatton G.I. Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites. Brain Res. 773 (1997) 162-172
38. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., and Uchimura H. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol. 341 (1998) 45-56